Sanofi (NASDAQ:SNY – Get Free Report) has been assigned an average recommendation of “Buy” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. Two research ...

Fintel reports that on March 21, 2025, Goldman Sachs initiated coverage of Sanofi - Depositary Receipt () (NasdaqGS:SNY) with a Neutral recommendation. As of March 19, 2025, the average one-year ...

It was developed with Sanofi (NASDAQ: SNY), who actually claims the revenues and splits profits with Regeneron. Regeneron posts their portion of Dupixent as collaboration revenue. Regeneron and ...

Below is Validea's guru fundamental report for SANOFI SA (ADR) (SNY). Of the 22 guru strategies we follow, SNY rates highest using our Acquirer's Multiple Investor model based on the published ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi presented positive results ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...

Sanofi develops therapeutic products for diabetes ... Here are a few to get you started, listed in alphabetical order. CoCrystal Pharma (NASDAQ:COCP) CoCrystal Pharma is a clinical-stage biotech ...

The Goldman Sachs Group started coverage on shares of Sanofi (NASDAQ:SNY – Free Report) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The firm issued a neutral ...

Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate ...

BRIDGEWATER, N.J., March 14, 2025 /PRNewswire/ -- Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the ...

Saint Gobain, Sanofi and L'Oreal are up 1 to 1.2% ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

First on this list of the top NASDAQ stem cell company stocks is multinational ... French multinational pharmaceutical company Sanofi develops therapeutic products for diabetes and cardiovascular ...

Renault, Air Liquide, Accor, Essilor, Pernod Ricard, Sanofi and Vivendi are advancing ... the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...